XML 58 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Segment - Schedule of Segment Reporting Information by Segment (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Stock-based compensation expense $ 4,530 $ 199
Interest and other expense 300  
Reconciliation of loss:    
Interest income (2,013) (1,623)
Adjustments and reconciling items (2,013)  
Net loss 52,673 $ 35,311
Clinical Research Segment [Member]    
Operating expenses:    
Direct program expense 27,398  
Indirect Program Expense 2,157  
Workforce salaries and benefits 15,102  
Stock-based compensation expense 4,530  
General corporate expenses 5,199  
Interest and other expense 300  
Reconciliation of loss:    
Net loss $ 54,686